• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Civitas looks to turn Parkinson’s patients “ON” with inhaled L-dopa

Some day in the not-too-distant future, a dry powder inhaler once used to deliver insulin may help Parkinson’s patients overcome some of the most debilitating symptoms of the disease.

Back in 2008, in the wake of the Exhubera failure, Eli Lilly backed out of its partnership with Alkermes on the AIR inhaled insulin project. As a result, Alkermes shuttered a $40 million, 90,000 sq. ft. production facility in Chelsea, MA that it had just built to manufacture insulin.

That facility now serves as the headquarters for Civitas, whose lead candidate, CVT-301, is an inhaled L-dopa for the treatment of motor fluctuations, called “OFF episodes,” in Parkinson’s patients. The product, which has shown promising results in Phase 2 trials, is based on the same inhalation technology platform as AIR insulin.

The Michael J. Fox Foundation for Parkinson’s Research provided funding for a Phase 2B trial, which recently completed enrollment, and in the fall of 2013, the company announced that it had raised $38 million for development of CVT-301 through Phase 3.

The ARCUS dry powder inhaler

The ARCUS dry powder inhaler

In January 2011, Civitas acquired all of the intellectual and physical property associated with the AIR platform when Alkermes spun out its respiratory business to the new company.

The AIR technology name came from its original developer, Advanced Inhalation Research, which was founded in 1997 by Robert Langer and David Edwards to commercialize large molecule inhalation powders developed at MIT and Penn State and which was acquired by Alkermes in 1999.

Thanks to the spin out, Civitas started off with an existing pipeline, GMP production facility, and technology platform. The company’s management also had extensive experience developing inhaled drugs, including co-founder and Chief Scientific Officer Rick Batycky who had helped to develop the AIR platform in the first place. What it lacked, says Batycky, was a name.

“When we started our series A, we had a different name. We had to change it at the request of investors, so we worked on that the day before closing the round,” he explains, and by the end, “It was kind of scrambling, like just pick one.”

The hasty selection may help explain the company’s unique pronunciation of its name. According to Batycky, “It was probably supposed to be pronounced “Siv’-ih-tahs,” but Sih-vee’-tas rolls a little easier off the tongue for us, so that’s how we say it.”

Civitas also renamed the inhalation platform, which is now known as “ARCUS.” The ARCUS platform includes both drug-only dry powder formulation technology and the breath-activated inhaler used to deliver large doses of drug.

ARCUS powders consist of porous particles with a very large geometric diameter in relation to their aerodynamic diameter. With few points of contact per volume, and therefore relatively low surface energy, the powder aerosolizes easily. CVT-301 has a geometric diameter of about 10 microns with an aerodynamic diameter of only about 3 microns, Batycky notes, and the ARCUS inhaler allows for delivery of tens of milligrams of the drug in a single inhalation.

“That’s important,” he says, “because L-dopa for the treatment of motor OFFs in Parkinson’s disease requires 20 -30 mg of drug delivered to the lung; we can do that in one or two inhalations.”

Share
1 2 3Next page »

published on March 5, 2014

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews